CYCN
NASDAQ
US
Cyclerion Therapeutics, Inc. - Common Stock
$6,15
▼ $-0,23
(-3,61%)
Vol. 11.2M
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$5.0M
ROE
-24,6%
Margine
-77,0%
D/E
0,00
Beta
0,96
52W
$1–$6
Consenso Wall Street
7 analisti · Mag 20232
Acquisto forte
4
Compra
1
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
AIXC
Aixcrypto Holdings Inc
$12.1M
LIXT
Lixte Biotechnology Holdings Inc
$31.5M
PSTV
Plus Therapeutics Inc
$70.4M
BOLD
Boundless Bio Inc
$26.9M
NEUP
Neuphoria Therapeutics Inc
$20.9M
LGVN
Longeveron Inc
$10.8M
SKYE
Skye Bioscience Inc
$24.0M
VTGN
Vistagen Therapeutics Inc
$26.1M
SNTI
Senti Biosciences Inc
$27.3M
Utili
Tasso di battuta: 40,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,39 | $-0,21 | +$0,18 |
| Set 2025 | — | $-0,30 | — |
| Giu 2025 | — | $-0,11 | — |
| Set 2023 | $-0,34 | $-0,93 | $-0,59 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | $194K | $1.8M | $81K | $93K | $875K |
| Utile netto | -$723K | $530K | -$1.4M | -$324K | -$976K |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -22.6% | -22.6% | -22.6% | -22.6% | -24.6% | -24.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -348.4% | -89.5% | -89.5% | -89.5% | -77.0% | -77.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.03 | 5.03 | 5.03 | 5.03 | 5.78 | 5.78 |
Rapporti chiave
ROA (TTM)
-22,4%
P/S (TTM)
1,75
P/B
1,0
EPS (TTM)
$-0,76
CF/Share
$-7,92
Crescita ricavi 3A
-20,2%
52W High
$6,25
52W Low
$1,28
$1,28
Intervallo 52 settimane
$6,25
Salute finanziaria
Flusso di cassa libero
-$264K
Liquidità
$4.6M
Aggiornato al Set 30, 2025
Як CYCN виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CYCN vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,8
▼
86%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
1,0
▼
60%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CYCN vs аналоги Biotechnology
ROE
-24,6%
▲
63%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-77,0%
▲
73%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-22,4%
▲
52%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя CYCN vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
5,8
▲
30%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
1,0
▼
1%
sotto
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів CYCN
CYCN
Mediana peer
Industria
CYCN прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CYCN vs аналоги: ключові метрики
Principali azionisti
Top 5: 6,43%Siren, L.L.C.
2,95%
$174K
Geode Capital Management, L…
1,10%
$65K
Two Sigma Investments, LP
1,06%
$63K
Two Sigma Advisers, LP
0,72%
$43K
Vanguard Group Inc
0,60%
$35K
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora